The Frontiers of Cardiovascular Medicine journal recently published the findings.
Midazolam that induces sleep and reduces anxiety in patients before surgery has been linked to a higher risk of heart illnesses when procedures are carried out at night.
The study was done by researchers from the University of Colorado Anschutz Medical Campus.
The outcomes demonstrate once again how the timing of a drug’s administration might affect its efficacy.
In this study, 1,773,118 occurrences in which the sedative midazolam was administered to 951,345 patients. They were assessed using the extensive Multicenter Perioperative Outcomes Group.
16,404 patients met the requirements for myocardial damage (MINS).
Researchers found that the time the medicine was delivered was important. This despite the fact that there was no association between delivering the treatment and the risk of heart injury in the total study population. When surgery was performed at night or on healthier patients, they discovered a substantial correlation between midazolam administration and the probability of MINS.
The causes are unknown, but they might be related to the PER2 gene, which produces a light-regulated protein that helps shield the heart from harm. Researchers discovered a connection between midazolam, circadian protein expression, and cardiac ischemia in animal studies. That shows midazolam disrupts the circadian clock in people, according to researchers.
The medication raises levels of the neurotransmitter GABA, which blocks some brain messages to have a relaxing effect.
Higher evening PER2 levels may then be less expressed as a result of this. When midazolam is administered at night the heart may become more vulnerable to harm as the levels drop.
Drugs are frequently given in the most effective way possible. However, the most effective solution could wind up being harmful.